[
    [
        {
            "time": "2019-11-08",
            "original_text": "复星医药(02196)11月8日将有1亿股非公开发行A股限售股上市流通 解禁",
            "features": {
                "keywords": [
                    "复星医药",
                    "限售股",
                    "解禁",
                    "非公开发行"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药(02196)11月8日将有1亿股非公开发行A股限售股上市流通 解禁",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-10-29",
            "original_text": "复星医药：前三季净利润同比下降1.45% 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利润",
                    "同比下降",
                    "盈利能力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药：前三季净利润同比下降1.45% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-10-29",
            "original_text": "复星医药：前三季度扣非净利润增长8.21%至17.22亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "扣非净利润",
                    "增长"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：前三季度扣非净利润增长8.21%至17.22亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-10-29",
            "original_text": "【民生医药|季报点评】复星医药：现金流持续上升，创新药上市有望带动利润率回升",
            "features": {
                "keywords": [
                    "复星医药",
                    "现金流",
                    "上升",
                    "创新药",
                    "利润率"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【民生医药|季报点评】复星医药：现金流持续上升，创新药上市有望带动利润率回升",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-10-29",
            "original_text": "复星医药旗下公司 召回5万支注射剂 产品问题",
            "features": {
                "keywords": [
                    "复星医药",
                    "召回",
                    "注射剂",
                    "产品问题"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药旗下公司 召回5万支注射剂 产品问题",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]